PartnershipUpdated on 31 March 2026
Microrobotic Platform for Targeted CNS Drug Delivery
About
Robeauté is a French MedTech company developing a microrobotic platform designed to enable precise, minimally invasive access to the brain parenchyma. Our technology allows controlled 3D navigation within brain tissue and enables multi-site intervention through a single entry point.
Initially developed for advanced biopsy applications, the platform is now being extended to enable localized intracerebral drug delivery. This approach addresses a key limitation in CNS therapeutics: the inability of many drugs to effectively reach target sites due to the blood-brain barrier and the lack of spatial control with existing delivery methods.
Robeauté’s platform enables targeted, multi-site delivery of therapeutics directly within brain tissue, opening new opportunities for the development of treatments in neuro-oncology, brain metastases, and neurodegenerative diseases.
We are exploring strategic partnerships with biotech and pharmaceutical companies to co-develop drug-device solutions for CNS indications. The objective is to combine innovative therapeutic compounds with a delivery platform capable of achieving precise local administration, improved efficacy, and reduced systemic toxicity.
We are particularly interested in collaborations involving therapies that require local delivery or are currently limited by blood-brain barrier penetration.
Organisation
Similar opportunities
Expertise
María de la Fuente
CEO/CSO at DIVERSA TECHNOLOGIES SL
Santiago de Compostela, Spain
Project cooperation
Stefano Brianza
Owner at Biomech Innovations AG
Nidau, Switzerland
Project cooperation
- Execution
- Biotech, Pharma and Cosmetics
- Coordinator looking for partners
Renaud Jacquemart
CEO at Omnium Global
Burlington, Canada